Antabio CEO Says M&A Is His ‘Exit Strategy’
‘Broken’ AMR Model Leaves Antibiotics Maker No Other Choice
Executive Summary
Antibiotics specialist Antabio aims to get enough funding to advance its pipeline far enough to become a takeover target.
You may also be interested in...
Finance Watch: The Rush To End 2023 With Fresh VC Cash For Biopharma
Private Company Edition: Playground’s third fund has $410m for tech, including biotech, Pivotal Life Sciences closed its second fund with $389m and Chugai will invest $200m through its new fund. Also, Tome launched with $213m, Sudo raised a $116m series B and Odyssey closed a $101m in series C.
AMR Crisis Experts See Hopeful Signs For 2020
2020 could be a watershed year in tackling AMR, but success needs market reforms that ensure new antibiotics get to market and prevent innovators going bust, experts tell Scrip.
Finance Watch: Intrexon Reorganizes, Raises Cash And Becomes Precigen
The new year starts with a strategic shift by Intrexon. Also, Roivant and Sumitomo Dainippon launch Sumitovant, Melinta reorganizes through Chapter 11 bankruptcy, Acorda arranges debt relief and CF PharmTech raises a $90m series E round.